SciELO - Scientific Electronic Library Online

 
vol.12 número1Validación de un ensayo ELISA para la determinación de anticuerpos anti LPS de Vibrio Cholerae índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Vaccimonitor

versión impresa ISSN 1025-028Xversión On-line ISSN 1025-0298

Vaccimonitor v.12 n.1 Ciudad de la Habana ene.-mar. 2003

 

ARTICULOS ORIGINALES

 

Dos décadas de Helicobacter pylori.

 

Two decades of Helicobacter pylori


Felipe Cava1 y Guillermo Cobas2


1 Centro de Biología Molecular "Severo Ochoa", Universidad Autónoma de Madrid. Madrid. España. E-mail: fcava@cbm.uam.es


2 Centro de Estudios de Biotecnología Universidad de Oriente. Santiago de Cuba. Cuba. E-mail:gcobas@cbm.uam.es


RESUMEN

Las enfermedades bacterianas son generalmente consideradas como problemas sanitarios serios, sin embargo, pueden a menudo solucionarse mediante una simple terapia antibiótica. Mucho más complicada es la curación de enfermedades fúngicas y virales. Muchos cánceres se pueden curar si el diagnóstico es temprano, pero la mayoría tienen un remedio casi tan perjudicial como la misma enfermedad. Otras enfermedades como las autoinmunes o las que afectan el corazón, simplemente son controladas, tratando de paliar los síntomas con medicamentos normalmente muy costosos. Por tanto, tenemos que comprender la sorpresa de la comunidad médica, cuando una enfermedad por mucho tiempo pensada incurable aunque controlable, se vio que estaba causada por una bacteria. Más aún, cuando desde siempre se había pensado que el microambiente del estómago era demasiado extremo como para albergar vida microbiana. Helicobacter pylori es la principal responsable de la formación de úlceras en la población mundial. Su capacidad de colonización y adaptación a ambientes hostiles le ha permitido sobrevivir y crecer en las condiciones adversas que ofrece el estómago. En esta revisión se resumen brevemente aspectos importantes de la historia del descubrimiento de tan relevante microorganismo, así como algunas características moleculares y clínicas de la patología que causa.

Palabras claves: Helicobacter pylori, patogénesis, infección.


ABSTRACT

Bacterial diseases are generally considered as serious sanitary problems. However, they can often be eradicated by using an antibiotic therapy. The healing of fungal and viral diseases is much more complicated. Many cancers can be cured if there is an early diagnosis, but the treatment of most of them is almost as harmful as the disease itself. Other diseases, such as the autoimmune and heart diseases are simply controlled by trying to palliate the symptoms with very expensive medicine. That’s why we must understand the astonishment of the medical community when a disease, long time considered incurable, although controllable, was found to be caused by a bacterium. This was even more so, because the stomach’s environment was considered too extreme to harbor any microbial life. Helicobacter pylori is the main agent of ulcer formation in the world population. Its colonization capacity and adaptability to hostile environments have allowed it to survive and grow in the harsh conditions of the stomach. In this review we briefly examine important aspects of the history of the discovery of such a relevant microorganism, as well as some molecular and clinical features of the pathology it produces.

Keywords: Helicobacter pylori, pathogenesis, infection.


Texto completo formato PDF

REFERENCIAS

1. Akopyants NS, Kersulyte D, and Berg DE. CagII, a new multigene locus associated with virulence in Helicobacterpylori. Gut. 1995:36:A1.

2. Appelmelk B J. et al. Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity. Infection and Immunity. 1996; 64:2031-2040.

3. Ashton-Key M, Diss TC, y Isaacson PG. Detection of Helicobacter pylori in gastric biopsy and resection specimens. Journal of Clinical Pathology. 1996; 49:107-111.

4. Benaissa M, et al. Changes in Helicobacter ultrastructure and antigens during conversion from the bacillary to the coccoid form. Infection and Immunity. 1996; 64:2331-2335.

5. Berg D E, Hoffman P S, Appelmelk BJ y Kusters JG. The Helicobacter pylori genome sequence: genetic factors for long life in the gastric mucosa. Trends in Microbiology. 1997; 5(12):468-474.

6. Blaser MJ. The bacteria behind ulcers. Scientific American. 1996:92-97.

7. Boot H y Jong D. Gastric lymphoma: the revolution of the past decade. Scandinavian Journal of Gastroenterology Supplement. 2002; 236:27-36.

8. Cave DR. How is Helicobacter pylori transmitted?.Gastroenterology.1997; 113:S9-S14.

9. Chan FK y Leung WK. Peptic-ulcer disease. Lancet. 2002; 360(9337):933-941.

10. Corthesy-Theulaz IB, et al. Naked DNA immunization against Helicobacter infection. Gastroenterology. 1996; 110:A889.

11. Covacci A y Rappuoli R. Helicobacter pylori: molecular evolution of a bacterial quasi-species. Current opinion in Microbiology. 1998; 1:96-102.

12. Covacci A, Falkow S, Berg DE y Rappuoli R. Did the inheritance of a pathogenity island modify the virulence of Helicobacter pylori?. Trends in microbiology. 1997; 5(5): 205-208.

13. Cover TL. An intracellular target for Helicobacter pylori vacuolating toxin. Trends in microbiology. 1998; 6(4):127-129.

14. Crabtree JE. et al. Helicobacter pylori induced interleukin-8 expression in gastric epithelial cells is associated with cag A positive phenotype. Journal of Clinical Pathology.1995; 48:41-45.

15. Cutler A. et al. Accuracy of invasive and noninvasive test to diagnose Helicobacter pylori infection. Gastroenterology. 1995; 109:136-141.

16. Davies GR. et al. Relationship between infective load of Helicobacter pylori and reactive oxygen metabolite production in antral mucosa. Scandinavian Journal of Grastroenterology. 1994; 29:419-424.

17. Devreker T, McNulty CAM, Uff JC, Wilkinson SP y Gear MWL. New spiral bacterium in gastric mucosa. Lancet. 1987; ii:96.

18. Dorrell N, Crabtree JE y Wren B. W. Host-bacterial interactions and the pathogenesis of Helicobacter pylori infection. Trends in microbiology. 1998; 6(10):379-383.

19. Dunn B. E, Cohen H y Blaser M. Helicobacter pylori. Clinical Microbiology Reviews. 1997:720-741.

20. Dunn B E. et al. Localization of Helicobacter pylori urease and heat shock protein homalog in human gastric biopsies. Infection and Immunity. 1997; 65:1181-1188.

21. Evans DJ. Jr, et al. Characterization of a Helicobacter pylori neutrophil-activating protein. Infection and Immunity. 1995; 63:2213-2220.

22. Ferrero RL, et al. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proceedings of the National Academy of Sciences of the United States of America. 1995; 92:6499-6503.

23. Ge Z, Hiratsuka K y Taylor DE. Nucleotide sequence and mutational analysis indicate that two Helicobacter pylori genes encode a p-type ATPase and a cation-binding protein associated with copper transport. Molecular Microbiology. 1995; 15-97-106.

24. Husson MO, Legrand D, Spik G y Leclerc H. Iron acquisition by Helicobacter pylori: importance of human lactoferrin. Infection and Immunity. 1993; 61:2694-2697.

25. Illingworth DS, Walter KS, Griffiths PL, y Barclay R. Siderophore production and iron-regulated envelope proteins of Helicobacter pylori. Int Journal of Medical Microbiology Virology Parasithology Infection Diseases. 1993; 280:113-119.

26. Kirschner DE y Blaser M. The dynamics of Helicobacter pylori colonization in relation to the host response. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96:8359-8364.

27. Kirschner DE y Blaser M. The dynamics of Helicobacter pylori infection of the human stomach. Journal of Theoretical Biology. 1995; 176:281-290.

28. Koletzko S, et al. Isotope-selective non-dispersive infrared spectroscopy for detection of Helicobacter pylori infection with 13C-urea breath test. Lancet. 1995; 345:961-962.

29. Kusters JG, Gerrits MM, Van Strijp JAG y Vandenbroucke-Grauls CMJE. Coccoid forms of Helicobacter pylori are the morphologic manifestation of cell death. Infection and Immunity. 1997; 3672-3679.

30. Lage AP, et al. Diagnosis of Helicobacter pylori infection by PCR: comparison with other invasive techniques and detection of cag A gene in gastric biopsy specimens. Journal of Clinical Microbiology. 1995; 33:2752-2756.

31. Li C F. et al. A newly developed PCR assay of H. pylori in gastric biopsy, saliva, and feces. Evidence of high prevalence of H. pylori in saliva supports oral transmission. Digestive Diseases and Sciences. 1996; 41:2142-2149.

32. Mannick EE, et al. Inducible nitric oxide synthase, nitrotyrosine and apoptosis y Helicobacter pylori gastritis: effect of antibiotics and antioxidants. Cancer Research. 1993. 56:3238-3243.

33. Misiewicz JJ, Harris AW, Bardhan KD, y Longworthy H. One week low dose triple therapy for eradication of H.pylori. A large multicentre randomyzed trial. Gastroenterology. 1996; 110:A198.

 

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons